Stock Events

Stock Events

Anebulo Pharmaceuticals 

$0.2418
2
-$0.02-7%Friday 15:33

Statistics

Day High
0.8699
Day Low
0.8699
52W High
2.75
52W Low
0.001
Volume
100
Avg. Volume
184
Mkt Cap
9.86M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Sep 23Expected
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
-0.14
-0.11
-0.07
-0.04
Expected EPS
-0.1
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.48MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANEB. It's not an investment recommendation.
Atlantic American
3
AAME
Apple
2
AAPL
AMD
2
AMD
Rocket Lab
2
RKLB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7B
Alkermes plc focuses on central nervous system (CNS) diseases, including treatments for addiction, which competes with Anebulo's focus on cannabinoid overdose treatment.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.3B
Jazz Pharmaceuticals acquired GW Pharmaceuticals, making it a key player in cannabinoid-based treatments, directly competing with Anebulo Pharmaceuticals.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.44B
ACADIA Pharmaceuticals specializes in CNS disorders, including treatments that could potentially overlap with Anebulo's focus areas.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.47B
Supernus Pharmaceuticals focuses on developing and commercializing products for CNS diseases, which could compete with Anebulo's product pipeline.
Pacira BioSciences
PCRX
Mkt Cap1B
Pacira BioSciences, Inc. specializes in non-opioid pain management, a market that could intersect with Anebulo's focus on treating cannabinoid-related conditions.

About

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Show More
CEO
Richard Anthony Cunningham
Employees
3
Country
United States
ISIN
US0345691036
WKN
000A3CM1D

Listings

OTC Link
US
ANEB
BOATS
BOATS
ANEB.BOATS

0 Comments

Share your thoughts

FAQs

What is Anebulo Pharmaceuticals stock price today?▼
The current price of ANEB is $0.24 USD — it has decreased by -7% in the past 24 hours. Watch Anebulo Pharmaceuticals stock price performance more closely on the chart.
What is Anebulo Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Anebulo Pharmaceuticals stocks are traded under the ticker ANEB.
Is Anebulo Pharmaceuticals stock price growing?▼
ANEB stock has fallen by -16.62% compared to the previous week, the month change is a -24.44% fall, over the last year Anebulo Pharmaceuticals has showed a -90.84% decrease.
What is Anebulo Pharmaceuticals market cap?▼
Today Anebulo Pharmaceuticals has the market capitalization of 9.86M
What is Anebulo Pharmaceuticals revenue for the last year?▼
Anebulo Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Anebulo Pharmaceuticals net income for the last year?▼
ANEB net income for the last year is -8.48M USD.
How many employees does Anebulo Pharmaceuticals have?▼
As of November 1, 2026, the company has 3 employees.
In which sector is Anebulo Pharmaceuticals located?▼
Anebulo Pharmaceuticals operates in the Health & Wellness sector.
When did Anebulo Pharmaceuticals complete a stock split?▼
Anebulo Pharmaceuticals has not had any recent stock splits.
Where is Anebulo Pharmaceuticals headquartered?▼
Anebulo Pharmaceuticals is headquartered in Lakeway, United States.